3/5
09:32 pm
ivvd
Invivyd Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Invivyd Q4 Earnings Call Highlights [Yahoo! Finance]
3/5
12:51 pm
ivvd
Invivyd, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
Invivyd, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/5
11:30 am
ivvd
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/5
07:41 am
ivvd
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates [Yahoo! Finance]
Low
Report
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates [Yahoo! Finance]
3/5
07:41 am
ivvd
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
Low
Report
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
3/5
07:03 am
ivvd
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
Low
Report
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
3/5
07:01 am
ivvd
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
Low
Report
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
3/2
04:40 pm
ivvd
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 [Yahoo! Finance]
Medium
Report
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 [Yahoo! Finance]
3/2
04:14 pm
ivvd
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/2
04:10 pm
ivvd
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
Medium
Report
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
3/2
04:01 pm
ivvd
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/26
08:03 am
ivvd
Invivyd (IVVD) had its "buy" rating reaffirmed by BTIG Research. They now have a $10.00 price target on the stock.
Low
Report
Invivyd (IVVD) had its "buy" rating reaffirmed by BTIG Research. They now have a $10.00 price target on the stock.
2/24
07:01 am
ivvd
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
Low
Report
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
2/3
07:52 am
ivvd
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration [Yahoo! Finance]
Low
Report
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration [Yahoo! Finance]
2/3
07:01 am
ivvd
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
Medium
Report
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
1/24
03:28 pm
ivvd
How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) [Yahoo! Finance]
Medium
Report
How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) [Yahoo! Finance]
1/22
10:45 am
ivvd
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention [Yahoo! Finance]
Low
Report
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention [Yahoo! Finance]
1/22
07:01 am
ivvd
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
Low
Report
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
1/21
07:17 am
ivvd
Invivyd (NASDAQ:IVVD) had its "buy" rating reaffirmed by analysts at BTIG Research.
Medium
Report
Invivyd (NASDAQ:IVVD) had its "buy" rating reaffirmed by analysts at BTIG Research.
1/20
07:01 am
ivvd
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
Medium
Report
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
1/14
02:21 pm
ivvd
?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 [Yahoo! Finance]
Medium
Report
?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 [Yahoo! Finance]
1/13
12:56 pm
ivvd
Adimab Records Another Year of Double-Digit Clinical Program Growth [Yahoo! Finance]
Low
Report
Adimab Records Another Year of Double-Digit Clinical Program Growth [Yahoo! Finance]
1/9
07:38 pm
ivvd
Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target [Yahoo! Finance]
Medium
Report
Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target [Yahoo! Finance]
1/8
07:01 am
ivvd
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Low
Report
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
12/31
11:21 am
ivvd
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda [Yahoo! Finance]
Low
Report
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda [Yahoo! Finance]